Figures & data
Table 1. Pharmacogenetic associations of genetic polymorphisms with cyclophosphamide.
Takada K
, ArefayeneM, DestaZ et al.: Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Arthritis Rheum.50(7) , 2202–2210 (2004).
Petros WP
, HopkinsPJ, SpruillS et al.: Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.J. Clin. Oncol.23(25) , 6117–6125 (2005).
Rocha V
, PorcherR, FernandesJF et al.: Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after hla-identical sibling hematopoietic stem cell transplantation for patients with leukemia.Leukemia23(3) , 545–556 (2009).
Su HI
, SammelMD, VeldersL et al.: Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.Fertil. Steril. (2009) (Epub ahead of print).
Rossi D
, RasiS, FranceschettiS et al.: Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large b-cell lymphoma treated with R-CHOP21.Leukemia23(6) , 1118–1126 (2009).
Yang G
, ShuXO, RuanZX et al.: Genetic polymorphisms in glutathione-S-transferase genes (gstm1, gstt1, gstp1) and survival after chemotherapy for invasive breast carcinoma.Cancer103(1) , 52–58 (2005).
Hohaus S
, MassiniG, D‘aloF et al.: Association between glutathione S-transferase genotypes and hodgkin‘s lymphoma risk and prognosis.Clin. Cancer Res.9(9) , 3435–3440 (2003).
Barahmani N
, CarpentieriS, LiXN et al.: Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.Neuro. Oncol.11(3) , 292–300 (2009).
Sweeney C
, AmbrosoneCB, JosephL et al.: Association between a glutathione s-transferase a1 promoter polymorphism and survival after breast cancer treatment.Int. J. Cancer103(6) , 810–814 (2003).
Sweeney C
, McclureGY, FaresMY et al.: Association between survival after treatment for breast cancer and glutathione S-transferase p1 Ile105Val polymorphism.Cancer Res.60(20) , 5621–5624 (2000).
Hohaus S
, Di Ruscio A, Di Febo A et al.: Glutathione S-transferase p1 genotype and prognosis in hodgkin‘s lymphoma. Clin. Cancer Res.11(6) , 2175–2179 (2005).
Dasgupta RK
, AdamsonPJ, DaviesFE et al.: Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.Blood102(7) , 2345–2350 (2003).
Stanulla M
, SchrappeM, BrechlinAM, ZimmermannM, WelteK: Polymorphisms within glutathione s-transferase genes (gstm1, gstt1, gstp1) and risk of relapse in childhood b-cell precursor acute lymphoblastic leukemia: a case–control study.Blood95(4) , 1222–1228 (2000).
Allan JM
, WildCP, RollinsonS et al.: Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.Proc. Natl Acad. Sci. USA98(20) , 11592–11597 (2001).
Zhong S
, HuangM, YangX et al.: Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.Br. J. Clin. Pharmacol.62(4) , 457–472 (2006).
Ekhart C
, RodenhuisS, SmitsPH, BeijnenJH, HuitemaAD: Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.Pharmacogenet. Genomics18(11) , 1009–1015 (2008).